MONALEESA-3: Updated Overall Survival Analysis of Ribociclib + Fulvestrant vs Placebo + Fulvestrant in Postmenopausal Patients With HR+/HER2- Advanced Breast Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
In this exploratory analysis performed at a median follow-up of approximately 4.5 years, ribociclib + fulvestrant maintained OS benefit vs placebo + fulvestrant in postmenopausal patients with HR+/HER2- advanced breast cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 258 KB
Released: June 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.

Related Content

Expert faculty provide insights into the role and utility of Ki-67 testing in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

person default Sunil Badve, MD, FRCPath Laura M. Spring, MD Released: September 26, 2022

Dr Denise Yardley discusses key ongoing trials in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

Denise A. Yardley, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: September 22, 2022 Expired: September 21, 2023

Downloadable slides from Dr Denise Yardley on key ongoing trials in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

Denise A. Yardley, MD Released: September 22, 2022

Slideset from Dr Denise Yardley on immunotherapy in early TNBC, from Clinical Care Options (CCO)

Denise A. Yardley, MD
Program Director
Released: September 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings